FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4365454254> ?p ?o ?g. }

• W4365454254 endingPage "7131" @default.
• W4365454254 startingPage "7131" @default.
• W4365454254 abstract "This study investigates the synthesis of a new compound, PYR26, and the multi-target mechanism of PYR26 inhibiting the proliferation of HepG2 human hepatocellular carcinoma cells. PYR26 significantly inhibits the growth of HepG2 cells (p < 0.0001) and this inhibition has a concentration effect. There was no significant change in ROS release from HepG2 cells after PYR26 treatment. The mRNA expressions of CDK4, c-Met and Bak genes in HepG2 cells were significantly inhibited (p < 0.05), while mRNA expression of pro-apoptotic factors such as caspase-3 and Cyt c was significantly increased (p < 0.01). The expression of PI3K, CDK4 and pERK proteins decreased. The expression level of caspase-3 protein was increased. PI3K is a kind of intracellular phosphatidylinositol kinase. PI3K signaling pathway is involved in signal transduction of a variety of growth factors, cytokines and extracellular matrix and plays an important role in preventing cell apoptosis, promoting cell survival and influencing cell glucose metabolism. CDK4 is a catalytic subunit of the protein kinase complex and is important for G1 phase progression of the cell cycle. PERK refers to phosphorylated activated ERK, which is translocated from cytoplasm to the nucleus after activation, and then participates in various biological reactions such as cell proliferation and differentiation, cell morphology maintenance, cytoskeleton construction, cell apoptosis and cell canceration. Compared with the model group and the positive control group, the tumor volume of the nude mice in the low-concentration PYR26 group, the medium-concentration group and the high-concentration group was smaller, and the organ volume was smaller than that in the model group and the positive control group. The tumor inhibition rates of low-concentration group PYR26, medium-concentration group and high-concentration group reached 50.46%, 80.66% and 74.59%, respectively. The results showed that PYR26 inhibited the proliferation of HepG2 cells and induced apoptosis of HepG2 cells by down-regulating c-Met, CDK4 and Bak, up-regulating the mRNA expression of caspase-3 and Cyt c genes, down-regulating PI3K, pERK and CDK4 proteins and up-regulating the protein level of caspase-3. In a certain range, with the increase in PYR26 concentration, the tumor growth was slower and the tumor volume was smaller. Preliminary results showed that PYR26 also had an inhibitory effect on the tumors of Hepa1-6 tumor-bearing mice. These results suggest that PYR26 has an inhibitory effect on the growth of liver cancer cells, therefore it has potential to be developed into a new anti-liver cancer drug." @default.
• W4365454254 created "2023-04-15" @default.
• W4365454254 creator A5008057462 @default.
• W4365454254 creator A5023397464 @default.
• W4365454254 creator A5031202827 @default.
• W4365454254 creator A5034702811 @default.
• W4365454254 creator A5039084645 @default.
• W4365454254 creator A5061890892 @default.
• W4365454254 creator A5067953128 @default.
• W4365454254 creator A5078988597 @default.
• W4365454254 creator A5083388017 @default.
• W4365454254 creator A5089890888 @default.
• W4365454254 date "2023-04-12" @default.
• W4365454254 modified "2023-09-25" @default.
• W4365454254 title "Design, Synthesis and Biological Evaluation of Multi-Target Anti-Cancer Agent PYR26" @default.
• W4365454254 cites W1690635788 @default.
• W4365454254 cites W1970299210 @default.
• W4365454254 cites W1971966577 @default.
• W4365454254 cites W1993996642 @default.
• W4365454254 cites W2027867588 @default.
• W4365454254 cites W2033090666 @default.
• W4365454254 cites W2033796679 @default.
• W4365454254 cites W2041862855 @default.
• W4365454254 cites W2050115670 @default.
• W4365454254 cites W2064090105 @default.
• W4365454254 cites W2069483548 @default.
• W4365454254 cites W2074350030 @default.
• W4365454254 cites W2075706012 @default.
• W4365454254 cites W2081053802 @default.
• W4365454254 cites W2104639622 @default.
• W4365454254 cites W2166805191 @default.
• W4365454254 cites W2341546369 @default.
• W4365454254 cites W2387426893 @default.
• W4365454254 cites W2530417471 @default.
• W4365454254 cites W3171622765 @default.
• W4365454254 cites W3214925036 @default.
• W4365454254 cites W4210360792 @default.
• W4365454254 cites W4214520590 @default.
• W4365454254 cites W4248583329 @default.
• W4365454254 cites W4301383457 @default.
• W4365454254 cites W4313251241 @default.
• W4365454254 doi "https://doi.org/10.3390/ijms24087131" @default.
• W4365454254 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37108294" @default.
• W4365454254 hasPublicationYear "2023" @default.
• W4365454254 type Work @default.
• W4365454254 citedByCount "0" @default.
• W4365454254 crossrefType "journal-article" @default.
• W4365454254 hasAuthorship W4365454254A5008057462 @default.
• W4365454254 hasAuthorship W4365454254A5023397464 @default.
• W4365454254 hasAuthorship W4365454254A5031202827 @default.
• W4365454254 hasAuthorship W4365454254A5034702811 @default.
• W4365454254 hasAuthorship W4365454254A5039084645 @default.
• W4365454254 hasAuthorship W4365454254A5061890892 @default.
• W4365454254 hasAuthorship W4365454254A5067953128 @default.
• W4365454254 hasAuthorship W4365454254A5078988597 @default.
• W4365454254 hasAuthorship W4365454254A5083388017 @default.
• W4365454254 hasAuthorship W4365454254A5089890888 @default.
• W4365454254 hasBestOaLocation W43654542541 @default.
• W4365454254 hasConcept C1491633281 @default.
• W4365454254 hasConcept C184235292 @default.
• W4365454254 hasConcept C185592680 @default.
• W4365454254 hasConcept C190283241 @default.
• W4365454254 hasConcept C29537977 @default.
• W4365454254 hasConcept C55493867 @default.
• W4365454254 hasConcept C62112901 @default.
• W4365454254 hasConcept C62478195 @default.
• W4365454254 hasConcept C79879829 @default.
• W4365454254 hasConcept C86554907 @default.
• W4365454254 hasConcept C86803240 @default.
• W4365454254 hasConcept C95444343 @default.
• W4365454254 hasConceptScore W4365454254C1491633281 @default.
• W4365454254 hasConceptScore W4365454254C184235292 @default.
• W4365454254 hasConceptScore W4365454254C185592680 @default.
• W4365454254 hasConceptScore W4365454254C190283241 @default.
• W4365454254 hasConceptScore W4365454254C29537977 @default.
• W4365454254 hasConceptScore W4365454254C55493867 @default.
• W4365454254 hasConceptScore W4365454254C62112901 @default.
• W4365454254 hasConceptScore W4365454254C62478195 @default.
• W4365454254 hasConceptScore W4365454254C79879829 @default.
• W4365454254 hasConceptScore W4365454254C86554907 @default.
• W4365454254 hasConceptScore W4365454254C86803240 @default.
• W4365454254 hasConceptScore W4365454254C95444343 @default.
• W4365454254 hasIssue "8" @default.
• W4365454254 hasLocation W43654542541 @default.
• W4365454254 hasLocation W43654542542 @default.
• W4365454254 hasLocation W43654542543 @default.
• W4365454254 hasOpenAccess W4365454254 @default.
• W4365454254 hasPrimaryLocation W43654542541 @default.
• W4365454254 hasRelatedWork W2350294409 @default.
• W4365454254 hasRelatedWork W2350542818 @default.
• W4365454254 hasRelatedWork W2354128257 @default.
• W4365454254 hasRelatedWork W2354735832 @default.
• W4365454254 hasRelatedWork W2367284899 @default.
• W4365454254 hasRelatedWork W2372283855 @default.
• W4365454254 hasRelatedWork W2375950882 @default.
• W4365454254 hasRelatedWork W2378222954 @default.
• W4365454254 hasRelatedWork W2382230817 @default.
• W4365454254 hasRelatedWork W4280493527 @default.

• next